Recent Updates
Recently added Catalysts
CRIS Neutral Sentiment

UPMC Hilman Cancer Center

Key Takeaway: The article provides an overview of the UPMC Hilman Cancer Center, detailing its management, collaborations, patient studies, and pipeline of treatments. It highlights current studies such as TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL, along with information on their drug pipeline including Emavusertib and Fimepinostat. The article serves as a comprehensive resource for investors and patients seeking information about the center's offerings and research.
Price reaction · baseline $109 (2024-10-22 close) · hit pre-market · 16 other CRIS headline(s) in the window, move may be shared
day 0 close · peak
-4.2%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~1 mo
High dilution risk
Lead asset
Emavusertib
Phase 2 · Chronic Lymphocytic Leukemia

Full Press Release Details

• About Company Overview Management Board of Directors Advisory Boards
• Collaborations Partner Collaborations Scientific & Research Collaborations
• Patients Patients Overview Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL Understanding Primary CNS Lymphoma Compassionate Use Policy
• Pipeline Pipeline Overview Emavusertib (CA-4948) Fimepinostat CA-170 CA-327
• Scientific Resources
• Investors Overview Press Releases Events and Presentations Corporate Governance Committee Composition Contact the Board Financial Information SEC Filings Annual Reports IRS Form 8937 Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage Contact Us
• Careers Life at Curis Open Positions Benefits
• Contact
• Company Overview
• Management
• Board of Directors
• Advisory Boards
• Partner Collaborations
• Scientific & Research Collaborations
• Patients Overview
• Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• Understanding Primary CNS Lymphoma
• Compassionate Use Policy
• Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• TakeAim Lymphoma
• TakeAim Leukemia
• TakeAim CLL
• Pipeline Overview
• Emavusertib (CA-4948)
• Fimepinostat
• CA-170
• CA-327
• Overview
• Press Releases
• Events and Presentations
• Corporate Governance Committee Composition Contact the Board
• Financial Information SEC Filings Annual Reports IRS Form 8937
• Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage
• Contact Us
• Committee Composition
• Contact the Board
• SEC Filings
• Annual Reports
• IRS Form 8937
• Interactive Chart
• Historical Stock Lookup
• Analyst Coverage
• Life at Curis
• Open Positions
• Benefits

Frequently Asked Questions

What studies are sponsored by UPMC Hilman Cancer Center?

UPMC Hilman Cancer Center sponsors studies such as TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL.

What drugs are in the pipeline at UPMC Hilman?

The pipeline includes drugs like Emavusertib (CA-4948), Fimepinostat, CA-170, and CA-327.

How can patients learn about current studies?

Patients can find information about current studies on the UPMC Hilman Cancer Center's website.

What collaborations does UPMC Hilman have?

UPMC Hilman Cancer Center engages in various partner and scientific collaborations.

Last updated: Oct 23, 2024